Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.

Drugs of today (Barcelona, Spain : 1998) - 1 Apr 2013

McPhail G L, Clancy J P

Abstract excerpt

Cystic fibrosis (CF) is a life-shortening disorder that affects over 30,000 people in the U.S. and 70,000 worldwide. CF is caused by mutations in the CFTR gene, which codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is a chloride and bicarbonate channel and regulates several ion transporters at the epithelial cell membrane, controlling hydration or ionic composition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Quality of Life
Share to Aminophenols
Share to Cell Membrane

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Epithelial Cells

Share to Mutation

Share to Quinolones

Source

Identifiers

PMID: 23616952
DOI: 10.1358/dot.2013.49.4.1940984

Genes

CFTR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.PMID 23616952Read ↗

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read ↗

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Semantic proximity Read ↗

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read ↗

New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Semantic proximity Read ↗

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.Semantic proximity Read ↗

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Semantic proximity Read ↗

Cystic Fibrosis Transmembrane Conductance Regulator–Modifying Medications: The Future of Cystic Fibrosis TreatmentSemantic proximity Read ↗

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.Semantic proximity Read ↗

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Semantic proximity Read ↗

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesSemantic proximity Read ↗

Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.Semantic proximity Read ↗

Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.